This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Prevention of post-herpetic neuralgia is the best management. Prompt use of oral anti-viral agents such as famciclovir and valaciclovir may reduce the duration and prevalence of post-herpetic neuralgia by up to 50% (1).

The evidence for the treatment with steroids is lacking. Most studies have shown either an indeterminate effect or no benefit (1).

Post-herpetic neuralgia may be treated with:

  • tricyclic antidepressants
  • anticonvulsants such as gabapentin
  • Capsaicin, a topical treatment made from chilli peppers, can be applied to the affected area several times per day (avoid any mucous membranes) (2)
  • oxycodone

A systematic review of the literature (3) concluded that tricyclic antidepressants have the strongest evidence of effectiveness in reducing pain or disability. The study also concluded that other treatments with some evidence of effectiveness include anticonvulsants (particularly gabapentin), capsacin and oxycodone.

Reference:

  1. Alper BS, Lewis PR (2000). Does treatment of acute zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. J Fam Pract, 49, 255-64.
  2. Prescriber (2001), 12 (20), 85-89.
  3. Alper BS, Lewis PR (2002). Treatment of postherpetic neuralgia. A systematic review of the literature. J Fam Pract; 51:121-8.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.